NYSE$CNC
Centene Corp · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
Centene reported solid revenue and earnings growth in Q1 2021 and increased its full-year guidance.
Centene Corporation announced its financial results for the first quarter ended March 31, 2021, reporting diluted earnings per share (EPS) of $1.19 and adjusted diluted EPS of $1.63. The company is increasing its full-year guidance, driven by the positive first quarter momentum.
- Managed care membership of 25.1 million, an increase of 1.3 million members, or 5%, compared to March 31, 2020.
- Total revenues of $30.0 billion, representing 15% growth compared to the first quarter of 2020.
- Diluted EPS of $1.19, compared to diluted EPS of $0.08 for the first quarter of 2020.
- Adjusted diluted EPS of $1.63, compared to $0.86 for the first quarter of 2020.
Headline financials
Revenue & EPS history
Centene · Revenue · Quarterly
$30B
Revenue by segment
Centene · $29.4B total across 4 segments · Q1 2021
- Medicaid$20.2B+18.5%68.7%
- Commercial$3.9B-5.4%13.3%
- Medicare$3.76B+24.6%12.8%
- Other$1.56B+24.5%5.3%
Forward guidance
The Company's annual guidance for 2021 is as follows: Total revenues (in billions) $120.1 - $122.1, GAAP diluted EPS $3.68 - $3.90, Adjusted diluted EPS $5.05 - $5.35, HBR 87.1% - 87.7%, SG&A expense ratio 8.4% - 8.9%, Adjusted SG&A expense ratio 8.3% - 8.8%, Effective tax rate 24.7% - 26.7%, Diluted shares outstanding (in millions) 589.0 - 592.0.
Tailwinds
- ongoing suspension of Medicaid eligibility redeterminations to August 1
- extensions of the California pharmacy services to July 1 and New York pharmacy services through 2022
- Marketplace special enrollment period
- recent Oklahoma contract awards
- Medicare membership, sequestration, and the fee schedule increase
Headwinds
- updated expectations regarding state premium rate adjustments
- updated expectations regarding state risk sharing mechanisms
- impact of COVID-19 on global markets
- impact of COVID-19 on economic conditions
- impact of COVID-19 on the healthcare industry
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
+0.4%
Avg return
Earnings day
+0.4%
Avg return
5 days after
+1.9%
Avg return
30 days after
54%
37 / 68 earnings
Positive
+13.8%
Q1 2014
Best reaction
-10.4%
Q2 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.5% | +22.6% | +33.9% | |
| Q4 2025 | -3.7% | +1.3% | +9.3% | |
| Q3 2025 | +12.5% | +3.9% | +18.5% | |
| Q1 2025 | -6.3% | -2.8% | -8.4% | |
| Q4 2024 | -5.4% | -9.1% | -8.3% | |
| Q3 2024 | +0.0% | +0.3% | -2.0% | |
| Q2 2024 | +9.0% | +14.1% | +16.5% | |
| Q1 2024 | -2.4% | -4.5% | -1.4% | |
| Q4 2023 | +1.1% | +4.4% | +7.5% | |
| Q3 2023 | -3.0% | -4.8% | +4.7% | |
| Q2 2023 | -2.7% | -3.7% | -9.2% | |
| Q1 2023 | -1.5% | +1.9% | -6.3% | |
| Q4 2022 | +2.7% | +2.4% | -7.7% | |
| Q3 2022 | +11.9% | +13.2% | +10.3% | |
| Q2 2022 | +0.6% | +1.1% | +4.1% | |
| Q1 2022 | -4.9% | -5.1% | -3.5% | |
| Q4 2021 | +6.4% | +3.1% | +4.5% | |
| Q3 2021 | +3.8% | +4.8% | +11.2% | |
| Q2 2021 | -4.0% | -5.6% | -12.5% | |
| Q1 2021 | -9.9% | -6.5% | +11.7% | |
| Q4 2020 | +4.8% | +1.6% | +6.3% | |
| Q3 2020 | -7.9% | -11.0% | -6.3% | |
| Q2 2020 | -1.4% | -3.0% | -10.1% | |
| Q1 2020 | -6.6% | -8.3% | -5.5% | |
| Q4 2019 | +5.1% | +0.4% | -5.0% | |
| Q3 2019 | +5.7% | +5.4% | +30.4% | |
| Q2 2019 | +3.0% | +2.4% | -12.7% | |
| Q1 2019 | +4.4% | +9.5% | +15.3% | |
| Q4 2018 | -2.9% | -3.2% | -13.2% | |
| Q3 2018 | -8.3% | -9.9% | -5.5% | |
| Q2 2018 | -3.1% | -3.0% | +6.0% | |
| Q1 2018 | -1.2% | -0.4% | +5.5% | |
| Q4 2017 | +5.0% | +2.3% | +0.9% | |
| Q3 2017 | -7.4% | -3.7% | -1.1% | |
| Q2 2017 | -1.0% | -1.8% | +2.1% | |
| Q1 2017 | +1.1% | +3.3% | +4.5% | |
| Q4 2016 | +7.9% | +9.1% | +9.3% | |
| Q3 2016 | +1.4% | +0.1% | -10.5% | |
| Q2 2016 | -10.4% | -6.3% | -10.0% | |
| Q1 2016 | +4.2% | — | — | |
| Q4 2015 | +2.2% | — | — | |
| Q3 2015 | +5.3% | — | — | |
| Q2 2015 | +0.2% | — | — | |
| Q1 2015 | -9.7% | — | — | |
| Q4 2014 | +5.6% | — | — | |
| Q3 2014 | +9.3% | — | — | |
| Q2 2014 | +5.8% | — | — | |
| Q1 2014 | +13.8% | — | — | |
| Q4 2013 | +4.5% | — | — | |
| Q3 2013 | -4.1% | — | — | |
| Q2 2013 | +5.1% | — | — | |
| Q1 2013 | +4.4% | — | — | |
| Q4 2012 | +6.1% | — | — | |
| Q3 2012 | +0.3% | — | — | |
| Q2 2012 | +6.9% | — | — | |
| Q1 2012 | -6.0% | — | — | |
| Q4 2011 | -2.5% | — | — | |
| Q3 2011 | +12.6% | — | — | |
| Q2 2011 | +3.3% | — | — | |
| Q1 2010 | +10.9% | — | — | |
| Q1 2011 | +2.4% | — | — | |
| Q4 2008 | -6.5% | — | — | |
| Q4 2010 | -6.5% | — | — | |
| Q3 2009 | -6.6% | — | — | |
| Q2 2009 | -6.6% | — | — | |
| Q3 2010 | -6.6% | — | — | |
| Q4 2009 | -5.3% | — | — | |
| Q2 2010 | -5.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro